Amyloid-β Inhibitor

BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC₅₀ = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease.

Toddacoumaquinone is a coumarin-naphthoquinone dimer found in the roots of Toddalia asiatica. Toddacoumaquinone inhibits acetylcholinesterase (AChE) and β-amyloid (Aβ_1-42) aggregation, with an IC₅₀ of 46 μM against electric eel acetylcholinesterase. Toddacoumaquinone exerts antiviral effects against herpes simplex virus type 1 and herpes simplex virus type 2 (HSV). Toddacoumaquinone is used in research related to Alzheimer's disease and herpesvirus infections.

PH-46A is an indane dimer with anti-inflammatory activity. PH-46A can reduced histological damage and serum amyloid A (SAA) levels in colitis mice.

TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β.

Phenchlobenpyrrone is a highly selective neuronal calcium antagonist that crosses the blood-brain barrier. Phenchlobenpyrrone mildly inhibits AChE activity. Phenchlobenpyrrone inhibits Aβ aggregation and promotes the clearance of Aβ oligomers. Phenchlobenpyrrone reduces abnormal phosphorylation of Tau protein. Phenchlobenpyrrone may be used in research on Alzheimer's disease.

D-687 is an inhibitor of Tau and Aβ. D-687 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties.

BACE1-IN-1 hydrochloride is an orally active, blood-brain barrier penetrant dual-target inhibitor of BACE1/2, with IC₅₀ values of 23 nM and 24 nM against human BACE1 and BACE2, respectively. BACE1-IN-1 hydrochloride reduces cerebral Aβ40 levels in mice. BACE1-IN-1 hydrochloride can be used in studies related to Alzheimer's disease and type 2 diabetes.

Glutaminyl Cyclase Inhibitor 5 (Compound 71) is a potent and selective human glutaminyl cyclase (hQC) inhibitor with an IC₅₀ of 3.2 nM.

Ginsenoside Re (Standard) is the analytical standard of Ginsenoside Re. This product is intended for research and analytical applications. Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

AChE/MAO-B-IN-3 (Compound D30) is a dual AChE and MAO-B inhibitor with IC₅₀s of 0.0257 μM and 0.0456 μM against human AChE and MAO-B, respectively. AChE/MAO-B-IN-3 can be used for the research of Alzheimer’s disease.

Cy3 labled Lepodisiran (LY3819469) sodium is a Cy3 labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease.

Glimepiride-d₈ (Glimperide-d₈; HOE-490-d₈) is deuterium-labeled Glimepiride (HY-B0104).

D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R).

MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research.

BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ₄₂ self-aggregation.

GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

SJ-300 is a potent and selective, orally active and brain-penetrat DKK3-LRP1 interaction inhibitor. SJ-300 restores Aβ clearance in AD models. SJ 300 binds to mLRPIV with a K_d of 7.9 μM, inhibits the DKK3 mLRPIV complex with an IC₅₀ of 3.2 μM, and does not disrupt the binding of Aβ to LRP1. SJ 300 rescues cognitive function and ameliorates neuropathology (Aβ plaque reduction ≈ 73.3 %) in vivo. SJ 300 can be employed for research in Alzheimer’s disease.

Beauveriolide III is an inhibitor of lipid droplet formation in mouse macrophages.

Multitarget AD-IN-5 (Compound 20), 9-Aminoacridine (HY-B1422) derivative, is a neuroprotective agent. Multitarget AD-IN-5 shows IC₅₀ values of 0.614, 0.448, 3.73 and 1.55 μM for hAChE, hBChE, hMAO-A and hMAO-B. Multitarget AD-IN-5 can reduce length and diameter of Aβ₄₂ fibers, and decrease the number of fibers per unit area. Multitarget AD-IN-5 can be used for research of Alzheimer's disease.

AJ-4 is an orally active, blood-brain barrier-permeable GSK-3β/AChE inhibitor, with an IC₅₀ of 4.7 nM against GSK-3β and 2.97 μM against AChE. AJ-4 increases the level of phosphorylated GSK-3β and reduces the expression of Amyloid-β and phosphorylated Tau. AJ-4 improves scopolamine-induced learning and memory impairment and alleviates hippocampal neuron damage in AD mice. AJ-4 can be used for the research of Alzheimer's disease.